APA (7th ed.) Citation

Curtin, F., Champion, B., Davoren, P., Duke, S., Ekinci, E. I., Gilfillan, C., . . . Bernard, C. (2020). A safety and pharmacodynamics study of temelimab, an antipathogenic human endogenous retrovirus type W envelope monoclonal antibody, in patients with type 1 diabetes. Diabetes, Obesity & Metabolism, 22(7), 1111. https://doi.org/10.1111/dom.14010

Chicago Style (17th ed.) Citation

Curtin, Francois, et al. "A Safety and Pharmacodynamics Study of Temelimab, an Antipathogenic Human Endogenous Retrovirus Type W Envelope Monoclonal Antibody, in Patients with Type 1 Diabetes." Diabetes, Obesity & Metabolism 22, no. 7 (2020): 1111. https://doi.org/10.1111/dom.14010.

MLA (9th ed.) Citation

Curtin, Francois, et al. "A Safety and Pharmacodynamics Study of Temelimab, an Antipathogenic Human Endogenous Retrovirus Type W Envelope Monoclonal Antibody, in Patients with Type 1 Diabetes." Diabetes, Obesity & Metabolism, vol. 22, no. 7, 2020, p. 1111, https://doi.org/10.1111/dom.14010.